 |
|
Acute hepatitis C virus infection: clinical update and remaining challenges
Chen-Hua Liu, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):623-642. Published online 2023 Feb 20 DOI: https://doi.org/10.3350/cmh.2022.0349
|
|
Citations to this article as recorded by
 Immune Responses to Anti-Hepatitis C Virus Antibodies during Pre-Liver Transplantation Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Recipients Associated with Post-Liver Transplantation Allograft Injury
Shu-Hsien Lin, Kun-Ta Wu, Chih-Chi Wang, Kuang-Tzu Huang, Li-Wen Hsu, Hock-Liew Eng, King-Wah Chiu
Antibodies.2024; 13(1): 7. CrossRef Direct-Acting Antiviral Treatment for Acute Hepatitis C in Japanese Patients: Clinical Course and Outcomes
Hiroshi Okano, Katsumi Mukai, Akira Nishimura
Cureus.2024;[Epub] CrossRef Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children
Chaowapong Jarasvaraparn, Christopher Hartley, Wikrom Karnsakul
Pathogens.2024; 13(2): 180. CrossRef Improving HCV diagnosis following a false-negative anti-HCV result
Xia Long, Yu Chen, Minggang Yin, Weiping Liu
Clinical Chemistry and Laboratory Medicine (CCLM).2024;[Epub] CrossRef Toward hepatitis C virus elimination using artificial intelligence
Moon Haeng Hur, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2024; 30(2): 147. CrossRef Una visión integral del manejo de la hepatitis C y el objetivo de erradicarla
Juan Carlos Restrepo-Gutiérrez
Hepatología.2024; 5(2): 120. CrossRef Contemporary Insights into Hepatitis C Virus: A Comprehensive Review
Malik Sallam, Roaa Khalil
Microorganisms.2024; 12(6): 1035. CrossRef Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals
Chen‐Hua Liu, Yu‐Ping Chang, Ji‐Yuh Lee, Chi‐Yi Chen, Wei‐Yu Kao, Chih‐Lin Lin, Sheng‐Shun Yang, Yu‐Lueng Shih, Cheng‐Yuan Peng, Fu‐Jen Lee, Ming‐Chang Tsai, Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao
Journal of Medical Virology.2024;[Epub] CrossRef Safety considerations in the management of hepatitis C and HIV co-infection
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Pablo Barreiro, Fernando de Jesus, Octavio Corral, Carmen de Mendoza
Expert Opinion on Drug Safety.2023; 22(5): 363. CrossRef Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials
Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari
Arabian Journal of Chemistry.2023; 16(8): 105013. CrossRef Oryza sativa L. Indica Seed Coat Ameliorated Concanavalin A—Induced Acute Hepatitis in Mice via MDM2/p53 and PKCα/MAPK1 Signaling Pathways
Zhiye Zhao, Ye Li, Shancheng Guo, Yuxu Chen, Haiaolong Yin, Yaxian Li, Guiguang Cheng, Lei Tian
International Journal of Molecular Sciences.2023; 24(19): 14503. CrossRef Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C
A. I. Gubenko, D. V. Goryachev, A. I. Muravieva, G. V. Shukshina
Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation.2023; 13(4): 519. CrossRef A Synopsis of Hepatitis C Virus Treatments and Future Perspectives
Christian Medina, Alexis Hipólito García, Francis Isamarg Crespo, Félix Isidro Toro, Soriuska José Mayora, Juan Bautista De Sanctis
Current Issues in Molecular Biology.2023; 45(10): 8255. CrossRef
|